Digest Network Come funziona
Network
/
Società
St
Non verificato

Stoke Therapeutics, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza

78 comunicati stampa

Guarda tutti i comunicati
29/10/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Salute
Biotecnologia
Medicina - Varie
Scienza
Farmaceutica
Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates
Fonte
Stoke Therapeutics, Inc.
Emittente
Business Wire
1.00
0
22/10/2026
Scienza
Biotecnologia
Farmaceutica
Salute
Igiene alimentare
Medicina - Varie
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial Updates
Fonte
Stoke Therapeutics, Inc.
Emittente
Business Wire
1.00
0
16/10/2026
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Mercato azionario
Finanza
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Fonte
Stoke Therapeutics, Inc.
Emittente
Business Wire
1.00
0
12/10/2026
Scienza
Igiene alimentare
Biotecnologia
Medicina - Varie
Salute
Farmaceutica
Ottica
Eventi
Industria
Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting
Fonte
Stoke Therapeutics, Inc.
Emittente
Business Wire
1.00
0
06/10/2026
Industria
Salute
Biotecnologia
Medicina - Varie
Scienza
Farmaceutica
Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting
Fonte
Stoke Therapeutics, Inc.
Emittente
Business Wire
1.00
0
05/10/2026
Industria
Scienza
Biotecnologia
Farmaceutica
Salute
Igiene alimentare
Medicina - Varie
Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
Fonte
Stoke Therapeutics, Inc.
Emittente
Business Wire
1.00
0
23/09/2026
Mercato del lavoro
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization
Fonte
Stoke Therapeutics, Inc.
Emittente
Business Wire
1.00
0
16/09/2026
Salute
Medicina - Varie
Sanità
Scienza
Biotecnologia
Mercato azionario
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Fonte
Stoke Therapeutics, Inc.
Emittente
Business Wire
1.00
0
03/09/2026
Mercato del lavoro
Eventi
Industria
Scienza
Biotecnologia
Farmaceutica
Salute
Igiene alimentare
Medicina - Varie
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
Fonte
Stoke Therapeutics, Inc.
Emittente
Business Wire
1.00
0
02/09/2026
Web e Social Network
Eventi
Fiere
Scienza
Igiene alimentare
Biotecnologia
Medicina - Varie
Sanità
Salute
Farmaceutica
Stoke Therapeutics to Present at the Cantor Global Healthcare Conference
Fonte
Stoke Therapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0